What is the appropriate treatment algorithm for a patient with suspected ileocecal Crohn’s disease after ileocolonoscopy, including management if intestinal tuberculosis is identified?

Treatment Algorithm for Suspected Ileocecal Crohn's Disease After Ileocolonoscopy

For mild to moderate ileocecal Crohn's disease, initiate ileal-release budesonide 9 mg once daily for 8 weeks, but first exclude intestinal tuberculosis in patients from endemic areas or with TB risk factors using dual testing (TST and IGRA) before starting any immunosuppressive therapy. 1

Step 1: Exclude Intestinal Tuberculosis Before Treatment

Who Requires TB Screening

• Patients born in or who lived for extended periods in TB-endemic areas 1
• Those with TB risk factors (night sweats, known TB contacts, positive chest imaging) 1
• All patients before initiating immunosuppressive therapy 1

Diagnostic Approach for TB vs. Crohn's

The differentiation is critical because misdiagnosis leads to catastrophic outcomes—treating TB with steroids causes dissemination, while treating Crohn's with anti-tubercular therapy delays appropriate immunosuppression. 2, 3, 4

Clinical features favoring intestinal tuberculosis: 1, 5, 3, 6

• Night sweats, fever, weight loss
• Concomitant pulmonary TB
• Involvement of fewer than 4 bowel segments
• Circular or transverse ulcers on colonoscopy
• Patulous ileocecal valve
• Mesenteric lymph nodes with calcification or central necrosis on imaging

Clinical features favoring Crohn's disease: 5, 3, 6

• Perianal disease (fissures, fistulas, abscesses)
• Bloody diarrhea
• Involvement of ≥4 bowel segments
• Longitudinal ulcers, aphthous ulcers, or cobblestone appearance
• Segmental small bowel involvement with skip lesions
• Comb sign and fibrofatty proliferation on CT enterography

TB Testing Strategy

Use dual testing (both TST and IGRA) in immunosuppressed patients or those from endemic areas to improve diagnostic yield, as both tests have reduced sensitivity with immunosuppression. 1 Perform IGRA before or concomitant with TST, as TST may boost IGRA results. 1

• Positive IGRA strongly suggests TB (90.91% sensitivity for ITB) 5
• Negative IGRA helps exclude TB (98.8% negative predictive value) 6
• If either test is positive with compatible clinical/endoscopic features, treat as probable TB 2, 5

Management When TB is Identified

If TB is diagnosed or highly suspected, initiate standard anti-tubercular therapy and delay biologic therapy for at least 4 weeks after starting chemotherapy. 1 In cases of greater clinical urgency, seek specialist infectious disease consultation. 1

For latent TB (positive screening, no active disease), complete chemoprophylaxis regimen before starting biologics: 1

• Isoniazid 300 mg daily for 6-9 months (with vitamin B6 to reduce neurotoxicity), OR
• Rifampicin 600 mg daily for 4 months (better adherence, not inferior to isoniazid)

Step 2: Treatment Based on Disease Severity

Mild to Moderate Ileocecal Crohn's Disease

First-line: Ileal-release budesonide 9 mg once daily for 8 weeks 1

• Achieves 51% remission rate (CDAI <150) with significantly fewer side effects than prednisolone 1
• Once-daily dosing is as effective as divided doses 1
• Taper over 1-2 weeks after achieving remission 1
• Budesonide is inferior to prednisolone in severe disease (CDAI >300) 1

Alternative if steroids contraindicated or patient preference: Exclusive enteral nutrition (EEN) for up to 8 weeks, though less effective in adults than pediatrics 1

Moderate to Severe Disease (CDAI >300)

Use systemic corticosteroids (prednisolone 40 mg daily, tapering by 5 mg weekly over 8 weeks) rather than budesonide. 1 Tailor the taper to disease severity and patient tolerance. 1

For severe disease requiring hospitalization: 1

• Intravenous hydrocortisone 400 mg/day or methylprednisolone 60 mg/day
• Consider concomitant IV metronidazole to distinguish active disease from septic complications

High-Risk or Aggressive Disease Features

Consider early biologic therapy in patients with: 1

• Complex disease (stricturing or penetrating) at presentation
• Perianal fistulizing disease
• Age <40 years at diagnosis
• Need for steroids to control index flare

Anti-TNF (infliximab), vedolizumab, or ustekinumab can be considered as first-line biologics in this population. 1 However, avoid infliximab in patients with obstructive symptoms. 1

Adjunctive Therapy Considerations

Azathioprine 1.5-2.5 mg/kg/day or mercaptopurine 0.75-1.5 mg/kg/day can be used as steroid-sparing agents, but slow onset of action (8-12 weeks) precludes use as sole therapy. 1

Step 3: Surgical Consideration

Laparoscopic ileocecal resection should be considered for: 1

• Patients failing or relapsing after initial medical therapy
• Limited ileocecal disease as primary therapy
• Patients preferring surgery to continuation of drug therapy

The LIR!C study demonstrated equivalence between laparoscopic resection and infliximab for terminal ileal disease failing conventional therapy, with resection being cost-effective. 1 Approximately 26% of surgical patients required infliximab within 4 years, while 39% of infliximab patients required surgery. 1

Critical Pitfalls to Avoid

1. Never start immunosuppressive therapy without excluding TB in at-risk populations—this can cause disseminated tuberculosis with fatal outcomes 1, 7

2. Do not rely on ileocolonoscopy alone—22.3% of patients have endoscopic skipping (normal terminal ileum but proximal small bowel inflammation), and 36.2% of strictures are missed without cross-sectional imaging 8

3. Avoid prolonged corticosteroid use—steroids are ineffective for maintenance and cause significant toxicity; taper appropriately and transition to steroid-sparing agents 1

4. Reassess at 2 months if empirical anti-TB therapy initiated—early mucosal response is an objective marker of TB treatment response and prevents delayed CD diagnosis 4